Format

Send to

Choose Destination
Brain. 2018 Oct 1;141(10):2855-2865. doi: 10.1093/brain/awy231.

Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial.

Author information

1
Centre de Référence Neuromusculaire Nord-Est-Ile de France, AP-HP, CHU Henri-Mondor Créteil 94010 France.
2
Sorbonne Université INSERM UMRS 974, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris France.
3
Institut de Myologie, CHU Pitié-Salpêtrière Paris 75013 France.
4
Public Health Department, AP-HP, Henri-Mondor Hospital; DHU A-TVB, IMRB-EA 7376 CEpiA UPEC Créteil 94010 France.
5
INSERM CIC1430, AP-HP, CHU Henri-Mondor Créteil 94010 France.
6
INSERM U861, I-Stem, Corbeil-Essonnes 91100 France.
7
UEVE U861, I-Stem, Corbeil-Essonnes 91100 France.
8
Institut des Biothérapies, Evry 91000 France.
9
CECS, I-Stem, Corbeil-Essonnes 91100 France.

Abstract

Metformin, the well-known anti-diabetic drug, has been shown recently to improve the grip test performance of the DMSXL mouse model of myotonic dystrophy type 1. The drug may have positively affected muscle function via several molecular mechanisms, on RNA splicing, autophagia, insulin sensitivity or glycogen synthesis. Myotonic dystrophy remains essentially an unmet medical need. Since metformin benefits from a good toxicity profile, we investigated its potential for improving mobility in patients. Forty ambulatory adult patients were recruited consecutively at the neuromuscular reference centre of Henri-Mondor Hospital. Participants and investigators were all blinded to treatment until the end of the trial. Oral metformin or placebo was provided three times daily, with a dose-escalation period over 4 weeks up to 3 g/day, followed by 48 weeks at maximum dose. The primary outcome was the change in the distance walked during the 6-minute walk test, from baseline to the end of the study. Concomitant changes in muscle strength and effect on myotonia, gait variables, biological parameters and quality of life were explored. Patients randomized into two arms eventually revealed similar results in all physical measures and in the mean 6-minute walk test at baseline. For the 23/40 patients who fully completed the 1-year study, differences between the groups were statistically significant, with the treated group (n = 9) gaining a distance of 32.9 ± 32.7 m, while the placebo group (n = 14) gained 3.7 ± 32.4 m (P < 0.05). This improvement in mobility was associated with an increase in total mechanical power (P = 0.01), due to a concomitant increase in the cranial and antero-posterior directions suggesting an effect of the treatment on gait. Subanalysis revealed positive effects of metformin treatment on the 6-minute walk test at the first intermediate evaluation (after 16 weeks of treatment), quantitatively similar to those recorded at 1 year. In contrast, except for the expected limited weight loss associated to metformin treatment, there was no change in any of the other secondary endpoints, including myotonia and muscle strength. Patients in the treated group had a higher incidence of mild-to-moderate adverse effects, mostly gastrointestinal dysfunctions that required symptomatic treatment. Although results were statistically significant only for the per protocol population of patients and not in the intent-to-treat analysis, metformin at the maximal tolerated dose provided a promising effect on the mobility and gait abilities of myotonic patients. These encouraging results obtained in a small-scale monocentric phase II study call for replication in a well-powered multicentre phase III trial.

PMID:
30169600
DOI:
10.1093/brain/awy231

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center